New CAR-T therapy IMV102 tested in Hard-to-Treat myeloma

NCT ID NCT07493135

Recruiting now Disease control Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called IMV102 for people with relapsed/refractory multiple myeloma, a type of blood cancer that has not responded to at least three prior therapies. IMV102 is a personalized therapy made from the patient's own immune cells (CAR-T cells). The study will enroll 30 participants to evaluate safety and how well the treatment works over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMV102 (a CAR-T cell therapy made from the patient's own immune cells)
What this could lead to: If successful, this could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small trial (30 people) focused on safety. The treatment may not work, and side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Beijing GoBroad Boren Hospital
RECRUITING

Beijing, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITING

Shanghai, China
The second affiliated hospital of Chongqing medical university
NOT_YET_RECRUITING

Chongqing, China
Zhengzhou Yihe Hospital
NOT_YET_RECRUITING

Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.